Exactus, Inc. operates in the healthcare sector, focusing on the development and commercialization of specialty and generic pharmaceuticals. The company's competitive position is challenged by its negative margins and lack of revenue generation, which are critical for sustaining operations and attracting investment.
Exactus, Inc. aims to generate revenue through the development of specialty pharmaceuticals and generics, leveraging its research capabilities. However, the company is currently not generating revenue, indicating significant operational challenges.
FDA approval of new drug applications
Partnerships or collaborations with larger pharmaceutical companies
Changes in regulatory environment affecting drug pricing
Market demand for specialty pharmaceuticals
Regulatory changes impacting drug approval processes
Technological disruptions in pharmaceutical development
Increased competition from generic drug manufacturers
Emergence of alternative therapies reducing demand for current offerings
Negative cash flow impacting operational sustainability
High operating losses leading to potential liquidity issues
low - the company's performance is less tied to GDP fluctuations due to its focus on niche pharmaceuticals.
Minimal impact from interest rates, as the company is not currently generating revenue and has low debt levels.
minimal - the company has a negative debt/equity ratio, indicating a lack of reliance on external financing.
growth - investors looking for high-risk, high-reward opportunities in the pharmaceutical sector.
high - the company's current operational challenges and lack of revenue contribute to significant stock price volatility.